Martínez-Castellanos and colleagues evaluated ocular function, neurodevelopment, and growth in infants treated with intravitreal bevacizumab injections for retinopathy of prematurity (ROP) during a ...

Please provide your email address to receive an email when new articles are posted on . Intravitreal bevacizumab may contribute to the need for longer ventilation support and a reduced chance of ...

Findings showed the difference in mean change in BCVA at week 12 between ONS-5010 and ranibizumab was -1.009 letters. Topline data were announced from a phase 3 trial demonstrating ONS-5010 ...

Off-label use of intravitreal bevacizumab therapy for ophthalmologic neovascular disorders began shortly thereafter. 11 Cases and series of cases of stage 3+, 4, and 5 retinopathy of prematurity have ...

Please provide your email address to receive an email when new articles are posted on . SEATTLE —There was no significant difference in cognitive outcomes for patients with retinopathy of prematurity ...

Credit: Getty Images. The Agency could not approve the BLA due to several CMC issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence. The Food and ...

Anti-VEGF use for ROP is expanding beyond bevacizumab and ranibizumab, with aflibercept’s fusion-protein structure conferring ...

This is a preview. Log in through your library . Abstract Purpose Patients with neovascular age-related macular degeneration (nARMD) will not deteriorate on visual acuity and retinal thickness when ...

Aflibercept was a less cost-effective treatment for retinal vein occlusion (RVO) compared with bevacizumab, although visual acuity outcomes were similar. Visual acuity outcomes were similar between ...